surmount-osa tirzepatide results SURMOUNT-5 (NCT05822830) top line announced. Adults w/ obesity + at least one of the following obesity-related diseases: htn, dyslipidemia, obstructive sleep apnea (OSA) or cvd, w/o dm weight loss of Tirzepatide after intensive lifestyle intervention
Description
Ozempic for binge eating: Is it effective
PlexusDx explains the mechanism and practical considerations for this stack
Retatrutide is a next-generation triple receptor agonist that targets GLP-1, GIP, and glucagon receptors
Zepbound is labeled as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) greater than 30 kg per m2, or a BMI greater than 27 kg per m2 and at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease).1
TRIUMPH-1 Phase 3 results: 28.3% weight loss at 80 weeks
Achieve sustainable, science-backed fat loss with personalized treatments designed to optimize metabolism, preserve muscle, and target stubborn fat
